Rewriting the rules of immunoconjugate therapies.
Location: United States, Massachusetts, Cambridge
Phone: +1 617-498-0020
Total raised: $99M
Founded date: 2001
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Rho Ventur... | rhoventure... |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
| 30.10.2023 | SymBiosis | symbiosis.... |
| - | Bain Capit... | baincapita... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.06.2016 | Series C | $33M | - |
| 02.03.2015 | Series B | $35M | - |
| 31.07.2012 | Series A | $27M | - |
| 24.10.2008 | - | $4M | - |
Mentions in press and media 18
| Date | Title | Description |
| 22.12.2022 | Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates | Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana's proprietary immunostimulatory platform Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory an... |
| 08.04.2020 | Mersana Therapeutics Raises $65 Million | CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers... |
| 18.04.2019 | When a new biotech’s drug pipeline is more of a ‘hypeline’ | The easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. For some early-stage companies, however, what would otherwise be a useful chart is better referred to as a “hypeline.” It’s a tongue-i... |
| 04.01.2019 | Deserted by Takeda, Mersana abandons lead drug | Mersana Therapeutics’ rocky road in developing its lead drug has culminated in the abandonment of the experimental cancer treatment, days after its high-profile partner Takeda decided to walk away from their deal. Ba... |
| 16.03.2018 | Longtime R&D chief Bischofberger leaves Gilead; Novartis operations chief heads out; Astellas taps Barretto-Ko to run Americas operations | Norbert Bischofberger → After a stretch of close to 30 years at Gilead $GILD, longtime R&D chief Norbert Bischofberger is leaving the company. He’ll be stepping out at the end of April, the latest in a whirlwind series of... |
| 28.06.2017 | Term Sheet — Wednesday, June 28 | Et Cetera Good morning! Some quick notes today… Paid Content What you need to know about growing cyberattacks From ExtraHop In other words, Binary is likely done. Remaining partner Jonathan Teo won’t be able to make new investments and his ... |
| 02.06.2017 | Term Sheet — Friday, June 2 | NEW MONEY, FOOD IPO Spin-outs: Last week we reported on the trend of junior partners at venture firms striking out on their own. In addition to the seven new firms we named in that article, here are two more worth watching: Paid Content How... |
| 16.06.2016 | Biotech Company Mersana Therapeutics Closes $33M Series C Financing | Mersana Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs), completed a $33m Series C financing. The round was led by new investor Wellington M... |
| 16.06.2016 | Mersana Therapeutics Raises $33M Series C Led by Wellington Management | CAMBRIDGE, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Fleximer® technology, today... |
| 02.03.2015 | Mersana Raises $35M in Series B | CAMBRIDGE, MA, Mersana Therapeutics, Inc., announced today that it raised $35 million in Series B-1 financing. >> Click here for more funding data on Mersana Therapeutics >> To export Mersana Therapeutics funding data to PDF... |
Show more